Undress the full metal jacket
Leave almost nothing behind by using our proven SeQuent® Please OTW DCB in combination with our spot stenting device VascuFlex® Multi-LOC.
SeQuent® Please OTW: A fruitful formulation
Paclitaxel with a drug dose of 3 μg/mm²
- Proven and effective drug dose1
- Homogeneous coating even in the balloon folds2
Resveratrol with positive characteristics
- Naturally occurring, plant based substance
- Anti-inflammatory, antioxidant & anti-hypertensive3,4
- Facilitates drug transfer into vessel wall2
CONSEQUENT randomized controlled trial
- 153 patients (78 DCB vs. 75 POBA)
- Rutherford 2-4 (95 % Grade 3-4)
- Diameter stenosis pre-procedure: 76.6 ± 18.1 %
- TASC C/D lesions: 23.5 %
- Mean lesion length 13.2 ± 10.4 cm
- Positive remodeling (LLL <0.00 mm) in DCB group: 36.5 %
- Predilatation: in only 55.6 % of cases
- Bailout stenting: 16.3 % (similar in both groups)
- Primary endpoint: 6-month angiographic late lumen loss
- Secondary endpoints: TLR, binary restenosis (> 50 %, PSVR > 2.4), walking distance, ABI at 6, 12 and 24 months
VascuFlex® Multi-LOC: Spot your lesions with short stents only!
- Six short stents on one delivery system
- Cover lesions only where it is really needed
- Maintain natural vessel movement
- Avoid full metal jackets
Features
- Short self-expanding Nitinol stents of 13 mm length each
- Stents with high radial force for highly calcified lesions2
- 5-8 mm stent diameters for SFA and popliteal arteries
- 0.035” guidewire compatibility; 6F sheath compatibility
LOCOMOTIVE all comers registry: Preliminary 12-month results12
- 75 patients
- Rutherford 2-5 (95 % Grade 3-5)
- Lesion treated in SFA & P1-P3 (mean RVD: 5.6 ± 0.7 mm)
- Mean lesion length 14.5 ± 9.0 cm
- Degree of stenosis: 88.4 %
- TASC C/D lesions: 51.1 %
- Primary endpoint: TLR at 6 months
- Secondary endpoints: TLR at 12 months; walking distance, ABI, patency, Rutherford, amputation at 6 and 12 months
1 Katsanos K et al. in J Endovasc Ther. 2016 Apr;23(2):356-70
2 Data on file at B. Braun
3 Ciccone G et al. in Curr Med Chem. 2013;20(10):1323-31
4 Magyar K et al. Clin Hemorheol Microcirc. 2012;50(3):179-87
5 Tepe G et al. Cardiovasc Intervent Radiol 2017;doi:10. 1007/s00270-017-1713-2
6 Schröder H Catheterization and Cardiovascular Interventions, Volume 86, Issue 2 August 2015 Pages 278-286
7 Werk M et al. Circ Cardiovasc Interv. 2012;5(6):831-840
8 Scheinert D et al. JACC Cardiovasc Interv. 2014;7(1):10-19
9 Zeller T et al. JACC Cardiovasc Interv. 2015;8(12):1614-1622
10 24-month results presented at LINC 2018
11 Amendt K et al. Vasa 2017;46(6):1-10
12 12-month results presented at LINC 2018
